Menu
ncarol.com
  • Home
  • Books
  • Book Release
  • Health
  • Business
  • Financial
  • Arts
  • Non-profit
  • Real Estate
ncarol.com

FreezeNit Announces Exclusive Licensing of Novel Non-Toxic Lice Treatment Technology
ncarol.com/10291348

Trending...
  • Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio
  • Cover Story about Matthew Cossolotto – Author of Harness Your PromisePower -- Published in July 2026 Enterprise World Magazine
  • From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)
FreezeNit
Naturally-Derived OTC Gel Eliminates Lice Without Neurotoxins, Launching Spring 2025

MARBLEHEAD, Mass. - ncarol.com -- FreezeNit, a leader in innovative lice treatment solutions, is thrilled to announce the exclusive licensing of a novel over-the-counter (OTC) lice treatment gel designed to provide a safe, naturally-derived, and highly effective alternative to traditional synthetic or pesticide-based lice treatments.

Unlike conventional OTC lice treatments that rely on pesticide-based pyrethroids, which have decreasing efficacy due to lice resistance, this new technology works by a purely mechanical method of action to eliminate lice and their eggs. The patented formula is free from harsh chemicals and instead leverages natural abrasives, such as diatomaceous earth and walnut shell powder, orange oil extract, and conditioning agents to physically shred lice and nits, while being gentle on the hair and scalp.

This addition strengthens FreezeNit's growing product portfolio, reinforcing the company's mission to provide clean, effective, science-backed treatments that parents can trust.

"This is an incredibly exciting milestone for FreezeNit," said Joanna Shu, CEO of FreezeNit. "By securing exclusive rights to this novel technology, we're positioned to be on the cutting edge of first aid treatments that are gentle on kids. Traditional lice treatments have failed parents and kids, but with this gel, lice don't stand a chance."

More on ncarol.com
  • Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)
  • NVM Pet Announces Leadership Transition, Promotes Next Generation of Executive Leadership
  • U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections

✔ Clinically Proven – was shown to be 96% effective in a clinical trial.
✔ No Resistance Issues – Unlike permethrin-based treatments, which have seen increased lice resistance, this technology works mechanically—not chemically—so lice cannot develop immunity.
✔ Patented & Protected – This novel formula and method of action is patented in the U.S., Canada, and the EU, ensuring exclusivity in the market.
✔ Class I, 510(k) Exempt – The FDA-regulated status allows for a fast-tracked market entry.

FreezeNit is actively engaging with retailers, distributors, and healthcare providers to bring this breakthrough lice treatment to families everywhere.

FreezeNit is an innovative healthcare company dedicated to revolutionizing first-aid with safe, effective, and science-backed solutions. By leveraging cutting-edge technology and natural alternatives to neurotoxins, FreezeNit provides families with fast, reliable, and pesticide-free treatments for head lice infestations.  For more information, visit www.FreezeNit.com.

Media Contact
Cathy Henry
cathy@freezenit.com
214-924-5992


Source: FreezeNit
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Lineus Medical Signs Partnership Agreement with DIMA MedTech to Support Expansion into Italy
  • New Research: Deterministic Decompilation of Hermes Bytecode Back to Readable JavaScript
  • Lionheart Holdings and KEO Energy Sign Letter of Intent for Proposed Business Combination
  • First Flight Society Celebrates National Aviation Day 2026 on Wednesday, August 19th
  • Marcus Christ Announces Singles: "The Hammer Goes Click" and "You Hate Me, I Hate You"
  • Nina Simone and Samuel Waymon Music Scholarship Fund Opens 2026/27 Application Cycle
  • Fatal FOMO May be Your Last Roll of the Dice
  • Inlow Upholstery Offers Dining Chair Reupholstery for Cleveland County Homeowners
  • Financial Visionary Kevin Foushee Expands Impact Through MTM LLC and Client-First Advisory Services
  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
  • Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio
  • Artists' Lives and Work are Intertwined
  • PokerStars & Ladbrokes veteran buys into Finnish news media Rahapelisanomat
  • Former Judge Chris Oldner Honored as Best Lawyer by "D Magazine" for 6th Straight Year
  • Missouri Hemp Businesses File Federal Lawsuit Challenging HB 2641
  • SUN Automation Group and KOLBUS America Align Hycorr Parts Support to Enhance Customer Service
  • Boston Industrial Solutions Launches New Citrine® SA1-370 Silicone Glue for Permanent Adhesion
  • Northeast Airlines Launches New Asset Management Group
  • AI Visibility Labs LLC - Dallas Texas - July 16 2026
  • NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
_catLbl0 _catLbl1

Popular on ncarol.com

  • RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project - 135
  • Sexually Abused in a Psychiatric Hospital or Psychiatrist's or Psychologist's Office? CCHR Urges Survivors to Reach Out to It - 124
  • Healthcare Leaders Publish New Integrated Behavioral Healthcare Guide, Led by Doctors of Behavioral Health - 104
  • Wagga Trucks set to expand to the Canberra Region as authorised dealer for Volvo, UD & Mack along with Freighter Group Trailers
  • BumblebeeSmart Announces Partnership with Extreme Kids World to Expand Access to Sensory Wall Panels and Educational Busy Boards
  • UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch
  • OneVizion Names AI Leader Matthew Kirk as Chief Operating Officer to Drive Governed AI Across Telecom and Electric Utilities
  • Director Sean McNamara Reunites with Award-Winning Cinematographer Shawn Seifert for Upcoming Feature Home
  • Triple-Digit Growth, Stock Market Upgrade plus a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)

Similar on ncarol.com

  • CRG Awarded NASA SEWP VI Contracts in Categories B and C
  • Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
  • Cover Story about Matthew Cossolotto – Author of Harness Your PromisePower -- Published in July 2026 Enterprise World Magazine
  • Missouri Hemp Businesses File Federal Lawsuit Challenging HB 2641
  • Rev-O-Box™ Launches Reversible Shipping Box That Instantly Becomes a Premium Gift Box
  • CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Lineus Medical Renews Agreement with Vizient, Delivering Enhanced Value for Vizient Members
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute